U.S. Office REITs Stock News

NasdaqGM:ZLAB
NasdaqGM:ZLABBiotechs

Zai Lab (ZLAB) Stock Could Be 47.5% Undervalued After China Approved TIVDAK

Zai Lab (ZLAB) stock is in focus after China’s National Medical Products Administration approved TIVDAK for adults with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy. See our latest analysis for Zai Lab. The NMPA approval for TIVDAK comes after a mixed stretch for Zai Lab, with the stock showing a 1-day share price return of 3.87% and a 7-day share price return of 7.58%, yet a 1-year total shareholder return that declined 56.36%. This suggests...
NasdaqGM:PSNL
NasdaqGM:PSNLLife Sciences

Personalis (PSNL) Stock Could Be 10% Undervalued After ASCO Cancer Data

Personalis (PSNL) stock is in focus after the company released new clinical data at the 2026 ASCO meeting, highlighting how its NeXT Personal test detects minimal residual disease across six solid tumor types. See our latest analysis for Personalis. The ASCO update comes after a sharp 53.93% 1 month share price return and a 37.50% 3 month share price return. The 1 year total shareholder return of 51.78% and very large 3 year total shareholder return indicate that momentum has been strong...
NasdaqGM:WVE
NasdaqGM:WVEPharmaceuticals

Wave Life Sciences (WVE) Stock Could Be 73% Undervalued After WVE 006 Data

Wave Life Sciences (WVE) is back in focus after recent data updates on its RNA editing platform, where lead program WVE-006 for alpha-1 antitrypsin deficiency showed dose-responsive, durable editing and an encouraging safety profile. See our latest analysis for Wave Life Sciences. Despite the encouraging WVE-006 data, Wave Life Sciences’ recent share price return has been weak. The stock is at US$6.00 after a 90-day share price decline of 51.85% and a year to date decline of 62.38%, while the...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Vera Therapeutics (VERA) Stock After FDA Trial Update Has The Valuation Gap Gone Too Far

Vera Therapeutics (VERA) stock is in focus after the company reached agreement with the FDA on an earlier eGFR analysis for its ORIGIN 3 trial of atacicept in IgA nephropathy. See our latest analysis for Vera Therapeutics. At a share price of $34.24, Vera Therapeutics has seen the 7 day share price return rise 7.84%, although the 90 day share price return is down 12.92% and the year to date share price return is down 29.58%. The 1 year total shareholder return of 56.70% and 3 year total...
NYSE:PIPR
NYSE:PIPRCapital Markets

Piper Sandler Companies (PIPR) Stock Could Be 80.3% Undervalued After Banking Leadership Reshuffle

Leadership reshuffle puts focus on services, industrials and private equity advisory Piper Sandler Companies (PIPR) stock is in focus after the firm reshaped its investment banking leadership, appointing new co-heads for services and industrials and forming a dedicated private equity advisory group. The reorganization places Rob Parker and Tripp Griffin in charge of services and industrials investment banking. Experienced dealmakers Matt Sznewajs, John Tye and David Lee are set to lead the...
NYSE:CNK
NYSE:CNKEntertainment

Is Cinemark’s Earnings Miss and Softer Outlook Altering The Investment Case For Cinemark Holdings (CNK)?

Cinemark Holdings recently reported Q4 2025 earnings of US$0.16 per share, falling short of the US$0.24 consensus estimate, although revenue slightly exceeded forecasts. This earnings miss, combined with a weak earnings outlook and a poorly ranked film and television production and distribution sector, highlights mounting pressure on Cinemark’s profitability expectations. Next, we will examine how Cinemark’s weaker-than-expected earnings and subdued industry outlook may influence the...
NYSE:IR
NYSE:IRMachinery

Ingersoll Rand Stock Leads Three US Industrial Quiet Compounders

With the Dow Jones at record highs, oil prices at a three month low and SpaceX reshaping the conversation around enterprise AI with a US$60 billion deal for Anysphere, the backdrop for large US industrial and multinational blue chip stocks looks very different from just a few months ago. Add in a closely watched first Federal Reserve decision under Kevin Warsh and renewed attention on resilient S&P 500 earnings, and it becomes important to separate headlines from practical portfolio ideas...
NYSE:CIM
NYSE:CIMMortgage REITs

How Chimera Investment’s Steady Dividend After Earnings Miss At Chimera Investment (CIM) Has Changed Its Investment Story

Chimera Investment Corporation’s Board of Directors has declared its second-quarter 2026 cash dividend of US$0.45 per common share, payable on July 31, 2026 to shareholders of record and ex-dividend on June 30, maintaining the same level as the first quarter despite a prior earnings miss. This reaffirmed dividend, alongside shareholder approval of directors and the 2026 auditor, underscores management’s emphasis on sustaining cash returns and signaling confidence in the REIT’s dividend...
NYSE:BLK
NYSE:BLKCapital Markets

BlackRock (BLK) Stock Could Be 20.2% Undervalued After BITA Launch

BlackRock (BLK) is back in focus after launching the iShares Bitcoin Premium Income ETF (Nasdaq: BITA), a new digital asset product that blends bitcoin exposure with an options-based monthly income approach. See our latest analysis for BlackRock. BlackRock’s recent BITA launch comes as the stock trades at US$1,052.23, with a 7 day share price return of 3.98% and a 90 day share price return of 8.67%. The 1 year total shareholder return of 10.84% points to momentum that has built over a longer...
NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

BioMarin Pharmaceutical (BMRN) Stock Could Be 36.7% Undervalued After ENDO 2026 Data

BioMarin Pharmaceutical (BMRN) drew fresh attention after presenting new VOXZOGO and BMN 333 data at ENDO 2026, reinforcing its focus on rare bone growth disorders and raising new questions for investors. See our latest analysis for BioMarin Pharmaceutical. Against this backdrop, BioMarin Pharmaceutical’s 1 month share price return of 7.41% stands in contrast to a year to date share price decline of 6.39%. Over 3 years, the total shareholder return is down 42.21%, suggesting momentum has been...
NYSE:AVA
NYSE:AVAIntegrated Utilities

Avista (AVA) Stock Could Be 4.3% Undervalued After Data Center Pause

Avista (AVA) recently paused new large data center energy requests, including talks on a prospective 500 MW project in Washington, after community concerns about its potential impact and the need for broader stakeholder alignment. See our latest analysis for Avista. The pause on data center requests has coincided with a 3.42% decline in Avista's 1 day share price return to $40.98 and a softer 7 day share price return of 2.43%. However, its year to date share price return of 5.84% and 1 year...
NasdaqCM:IGIC
NasdaqCM:IGICInsurance

International General Insurance Holdings (IGIC) Stock Could Be 36% Below Fair Value After India Approval

International General Insurance Holdings (IGIC) stock is drawing attention after the company received approval from India’s International Financial Services Centres Authority to establish a reinsurance branch in GIFT City, India’s flagship international financial hub. See our latest analysis for International General Insurance Holdings. The GIFT City approval comes as International General Insurance Holdings trades at US$25.01. Recent share price returns over 3 months and 1 month suggest...
NYSE:AXP
NYSE:AXPConsumer Finance

American Express (AXP) Is Buying TheFork To Expand Its European Dining Reach

American Express (NYSE:AXP) announced an agreement to acquire TheFork, a European restaurant reservation platform, from Tripadvisor. TheFork works with more than 50,000 restaurant partners across 11 countries in Europe. The deal is intended to expand American Express’s global dining network and its dining related benefits for cardholders. American Express is best known for its payments network and card services. In recent years the company has been putting more weight on travel, dining, and...
NasdaqGS:AMSC
NasdaqGS:AMSCElectrical

American Superconductor (AMSC) Stock Could Be 22% Undervalued as Grid Spending Narrative Builds

American Superconductor (AMSC) has drawn investor attention after recent trading swings, with the stock up about 2.6% in the latest session but down roughly 25% over the past month. See our latest analysis for American Superconductor. Set against its latest share price of $41.07, American Superconductor’s recent 30 day share price return of down 25.4% contrasts with a 90 day share price return of up 31.8% and a 1 year total shareholder return of 38.7%. This suggests momentum has cooled after...
NYSE:BTU
NYSE:BTUOil and Gas

Peabody Energy (BTU) Stock Could Be 24.2% Undervalued After Bonding Overhaul

Peabody Energy (BTU) has reworked its Australian mine reclamation bonding, replacing fully cash backed programs with A$700,000,000 in asset backed surety facilities and updating its revolving credit agreement to support this new structure. See our latest analysis for Peabody Energy. Peabody Energy's shift to asset backed surety facilities comes after a mixed period for the stock, with the share price falling 26.5% over the past 90 days but delivering a 93.6% total shareholder return over the...
NYSE:DECK
NYSE:DECKLuxury

Deckers (DECK) Loses Ugg Boot Patent As Jury Backs Quince

Federal jury rules in favor of Quince in a design patent dispute with Deckers Outdoor over the Ugg Classic Ultra Mini Boot. Verdict invalidates Deckers Outdoor's design patent covering the Ugg Classic Ultra Mini Boot. Decision affects enforcement of intellectual property tied to one of Deckers' Ugg products. Deckers Outdoor (NYSE:DECK), the company behind Ugg, Hoka, Teva and other footwear brands, now faces a fresh legal backdrop after the Ugg Classic Ultra Mini Boot design patent was...
NasdaqGS:FBNC
NasdaqGS:FBNCBanks

Does First Bancorp’s (FBNC) New Dividend Level Quietly Redefine Its Capital Allocation Priorities?

Earlier this month, First Bancorp’s Board of Directors declared a US$0.24 per-share cash dividend on its common stock, payable on July 24, 2026 to shareholders of record as of June 30, 2026. The dividend decision follows a first quarter in which management highlighted an expanding net interest margin, stable credit quality, and tight expense control as support for ongoing shareholder payouts. We’ll now examine how this dividend declaration, backed by expanding net interest margins, shapes...
NYSE:KOF
NYSE:KOFBeverage

Coca Cola FEMSA (NYSE:KOF) Replaces Coca Cola Board Representative With Sedef Salingan Sahin

The Coca-Cola Company has adjusted its board representation at Coca-Cola FEMSA (NYSE:KOF). Mrs. Jennifer K. Mann resigned as Director and has been replaced by Mrs. Sedef Salingan Sahin. This change reflects an update in the oversight role of The Coca-Cola Company's shareholding block within KOF's governance. Coca-Cola FEMSA, a key bottling partner for Coca-Cola products in Latin America, sits at the intersection of beverage brands and local distribution networks. For investors tracking...
NasdaqGS:SCSC
NasdaqGS:SCSCElectronic

Does ScanSource’s Revenue Beat And IT Demand Surge Change The Bull Case For SCSC?

Earlier this quarter, ScanSource reported a strong first-quarter performance, with revenues surpassing analyst expectations on the back of rising demand for IT distribution and solutions. An interesting aspect of the update was CEO Mike Baur’s emphasis on the company’s solid operational execution, underscoring how core business strength supported the earnings outperformance. We’ll now examine how ScanSource’s revenue beat, fueled by stronger IT distribution demand, influences the company’s...
NYSE:NSC
NYSE:NSCTransportation

Norfolk Southern (NSC) Stock Could Be 7.6% Undervalued As PSR 2.0 Shapes The Narrative

Norfolk Southern (NSC) stock has drawn renewed attention after recent trading moves, with investors weighing its rail-focused business against mixed short term performance, including a decline over the past month along with gains over the past 3 months. See our latest analysis for Norfolk Southern. At a share price of $310.28, Norfolk Southern has seen mixed short term share price momentum, while the 1 year total shareholder return of 25.35% and 3 year total shareholder return of 47.79% point...
NYSE:SNX
NYSE:SNXElectronic

How Investors Are Reacting To TD SYNNEX (SNX) Expanding Post-Quantum Security And HPE Ecosystem Partnerships

In early June 2026, EigenQ Inc. announced a collaboration with TD SYNNEX to help organizations modernize AMD EPYC-based server environments for post-quantum security, while ConnectSecure expanded access to its vulnerability and compliance platform through TD SYNNEX’s distribution network. These agreements, alongside multiple 2026 HPE Partner of the Year awards and expanded global distribution status, highlight TD SYNNEX’s role at the center of advanced cybersecurity and infrastructure...
NasdaqGS:CLBT
NasdaqGS:CLBTSoftware

Will Cellebrite’s AI‑Powered Genesis Platform Redefine Cellebrite DI's (CLBT) Narrative on Evidence Analysis?

Cellebrite DI Ltd. recently announced the past general availability of Cellebrite Genesis, an AI-powered investigative platform that helps law enforcement and other agencies rapidly analyze more than 35 digital evidence formats while maintaining privacy controls, legal guardrails and clear traceability to source data. Built on over 25 years of investigative experience and validated in early access by hundreds of agencies worldwide, Genesis aims to compress workloads from weeks to minutes and...
NasdaqGS:APA
NasdaqGS:APAOil and Gas

APA (APA) Stock Could Be 66% Overvalued After Recent Pullback

APA (APA) stock has pulled back, with the share price down 6% over the past day and 8% over the past week. This invites a closer look at how its operations and recent performance stack up for investors. See our latest analysis for APA. The recent 1 month share price return of down 10.8% and 3 month share price return of down 3.1% suggest that near term momentum for APA is fading, even though the year to date share price return of 37.1% and 1 year total shareholder return of 76.7% still point...
NYSE:PR
NYSE:PROil and Gas

Did Prospective Iranian Oil Sanctions Relief Just Shift Permian Resources' (PR) Investment Narrative?

A recent peace agreement between the U.S. and Iran opened a 60-day negotiation on lifting Iranian oil sanctions, raising the prospect of roughly 3 million barrels per day of Iranian exports returning to global markets and pressuring oil prices and energy producers such as Permian Resources. This potential supply overhang underscores how sensitive U.S. shale operators are to geopolitical shifts that can quickly alter global oil balances and market expectations. We’ll now examine how the...